Eliem Therapeutics Buy Hold or Sell Recommendation
| ELYMDelisted Stock | USD 3.04 0.04 1.30% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eliem Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Eliem Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Eliem Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Eliem and provide practical buy, sell, or hold advice based on investors' constraints. Eliem Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
Eliem |
Execute Eliem Therapeutics Buy or Sell Advice
The Eliem recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eliem Therapeutics. Macroaxis does not own or have any residual interests in Eliem Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eliem Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Eliem Therapeutics Trading Alerts and Improvement Suggestions
| Eliem Therapeutics is now traded under the symbol CLYM. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Eliem Therapeutics generated a negative expected return over the last 90 days | |
| Eliem Therapeutics has high historical volatility and very poor performance | |
| Eliem Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN |
Eliem Therapeutics Returns Distribution Density
The distribution of Eliem Therapeutics' historical returns is an attempt to chart the uncertainty of Eliem Therapeutics' future price movements. The chart of the probability distribution of Eliem Therapeutics daily returns describes the distribution of returns around its average expected value. We use Eliem Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eliem Therapeutics returns is essential to provide solid investment advice for Eliem Therapeutics.
| Mean Return | -0.87 | Value At Risk | -9.35 | Potential Upside | 6.21 | Standard Deviation | 5.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eliem Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eliem Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eliem Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eliem Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eliem delisted stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.72 | |
β | Beta against Dow Jones | -1.27 | |
σ | Overall volatility | 4.86 | |
Ir | Information ratio | -0.19 |
Eliem Therapeutics Volatility Alert
Eliem Therapeutics exhibits very low volatility with skewness of 0.14 and kurtosis of 2.58. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eliem Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eliem Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eliem Therapeutics Fundamentals Vs Peers
Comparing Eliem Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eliem Therapeutics' direct or indirect competition across all of the common fundamentals between Eliem Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eliem Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eliem Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eliem Therapeutics to competition |
| Fundamentals | Eliem Therapeutics | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Current Valuation | 122.66 M | 16.62 B |
| Shares Outstanding | 67.06 M | 571.82 M |
| Shares Owned By Insiders | 10.38 % | 10.09 % |
| Shares Owned By Institutions | 77.67 % | 39.21 % |
| Number Of Shares Shorted | 1.15 M | 4.71 M |
| Price To Book | 1.56 X | 9.51 X |
| EBITDA | (40.27 M) | 3.9 B |
| Net Income | (35.12 M) | 570.98 M |
| Cash And Equivalents | 122.95 M | 2.7 B |
| Cash Per Share | 4.63 X | 5.01 X |
| Total Debt | 349 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 17.48 X | 2.16 X |
| Book Value Per Share | 3.33 X | 1.93 K |
| Cash Flow From Operations | (20.6 M) | 971.22 M |
| Short Ratio | 4.07 X | 4.00 X |
| Earnings Per Share | (2.22) X | 3.12 X |
| Target Price | 4.5 | |
| Number Of Employees | 9 | 18.84 K |
| Beta | -0.35 | -0.15 |
| Market Capitalization | 346.03 M | 19.03 B |
| Total Asset | 110.47 M | 29.47 B |
| Retained Earnings | (155.98 M) | 9.33 B |
| Working Capital | 107.42 M | 1.48 B |
| Net Asset | 110.47 M |
Note: Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3 [view details]
Eliem Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eliem . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Eliem Therapeutics Buy or Sell Advice
When is the right time to buy or sell Eliem Therapeutics? Buying financial instruments such as Eliem Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Eliem Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |